Canada · Delayed Price · Currency is CAD Manulife Financial Earnings Call Transcripts
Fiscal Year 2026
-
Management reaffirmed an 18% ROE target for 2027, with recent progress despite U.S. mortality losses. Asia remains a growth driver, though regulatory changes in Hong Kong will impact earnings. The Comvest acquisition strengthens private credit capabilities, and capital allocation is focused on measured buybacks and portfolio optimization.
Fiscal Year 2025
-
Delivered record core earnings and double-digit new business CSM growth in 2025, supported by strong Asia and Global WAM performance, robust capital metrics, and strategic investments. Confident in achieving 2027 targets, with continued focus on digital innovation and disciplined capital allocation.
-
A refreshed strategy targets balanced growth across Asia, Canada, and the U.S., with a focus on AI-driven value, stable capital allocation, and selective M&A. Asia remains a key growth driver, while legacy risk is being reduced and ROE targets are on track for 2027.
-
A new strategic chapter is underway, focusing on global growth, especially in the U.S., Canada, and Asia, with AI as a key differentiator. The company is leveraging organic growth, disciplined risk management, and capital efficiency, while maintaining robust shareholder returns and preparing for long-term success.
-
Q3 2025 saw record core earnings, 16% core EPS growth, and strong results in Asia and Global WAM, despite net outflows in asset management. A refreshed strategy emphasizes balanced growth, digital innovation, and a new India JV, with robust capital returns and a strong balance sheet.
-
A smooth CEO transition has set the stage for renewed optimism and a customer-focused strategy, with confidence in meeting 2027 targets and driving long-term growth. Strategic investments, especially in Asia and GWAM, are prioritized, while capital strength supports both organic and inorganic opportunities.
-
Q2 2025 saw strong top-line growth, with net income up $747M year-over-year and robust segment performance in Asia and Global WAM. The $937.5M Comvest acquisition will scale private credit, is immediately accretive, and does not impact buybacks. LICAT ratio remains strong at 136%.
-
The meeting highlighted strong financial results, major reinsurance deals, and leadership transitions. New strategic targets were set, digital and sustainability initiatives advanced, and all voting items passed with strong support. Key risks discussed included macroeconomic volatility and climate change.
-
Q1 2025 saw strong growth in Asia and Global WAM, with APE sales up 50% in Asia and positive net flows in WAM. Core EPS rose 3% despite one-time charges, and capital ratios remain robust. Management expects continued momentum, with normalization of growth rates and ongoing resilience amid macro uncertainty.
-
Management targets 18% ROE by 2027, leveraging strong growth in wealth and Asia, disciplined capital return, and operational excellence. Illiquid asset headwinds are easing, and further long-term care transactions are likely. Remittances and cash conversion remain robust.
Fiscal Year 2024
-
Record core earnings surpassed CAD 7 billion, driven by Asia and Global WAM, with strong growth in APE sales, new business value, and remittances. Capital was returned to shareholders via increased dividends and buybacks, while digital transformation and disciplined expense management supported efficiency gains.
-
Roy Gori reflected on his tenure, highlighting the completion of a major transformation, strong financial and cultural progress, and the company's readiness for future growth under new leadership. Digital innovation and Asia's expansion remain key priorities, with ambitious 2027 targets in place.
-
A second major LTC reinsurance deal with RGA will reduce reserves by 18% and release $800 million in capital for share buybacks, supporting an 18%+ ROE target. Digital and organic initiatives are driving further value, while LTC now represents just 10-11% of core earnings.
-
Record Q3 results driven by strong growth in Asia and Global WAM, robust digital transformation, and disciplined capital returns. Core earnings, APE sales, and book value per share all rose sharply, with continued momentum toward ambitious medium-term targets.
-
Q2 saw strong growth in APE sales, core earnings, and book value, with Asia and Global WAM leading performance. Share buybacks accelerated, capital position remains robust, and new targets for ROE and remittances were set for 2027.
-
A comprehensive transformation has driven higher ROE, efficiency, and digital leadership, positioning the business for growth across core markets. Strategic investments in AI, automation, and health platforms support expansion into underserved segments and reinforce a culture of innovation and partnership.
-
Raised financial targets include 18%+ core ROE, 10%-12% EPS growth, and CAD 22B in remittances for 2024-2027, driven by digital investment, portfolio optimization, and focus on Asia and GWAM. Disciplined capital allocation, risk reduction, and strong cash generation underpin confidence in sustainable growth.